Ranbaxy `systematically violated` good manufacturing practices: Whistleblower

Ranbaxy Laboratories "systemically violated" good manufacturing practices, says the whisteblower whose alert led to a US probe, a day after India`s top drugmaker agreed to pay a hefty USD 500 million to settle charges over its adulterated drugs.

US SC rules for generic drugmaker on patent

The US Supreme Court ruled on Tuesday in favor of a generic drugmaker in a case over how companies can fight brand-name rivals in an effort to get their cheaper medicines to market.

US SC rules for generic drugmaker on patent

The US Supreme Court ruled on Tuesday in favor of a generic drugmaker in a case over how companies can fight brand-name rivals in an effort to get their cheaper medicines to market.